Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Emerging COVID-19 serology tests aim for neutralizing antibodies

New COVID-19 serology tests focus on the antibodies believed most likely to block viral entry

June 11, 2020 5:29 PM UTC

The next wave of serology tests from big diagnostic players could get closer to telling people whether they are protected from COVID-19 by homing in on the antibodies most likely to block viral entry into cells. The new entrants highlight how far industry remains from defining ideal tests for COVID-19 exposure and immunity.

FDA has granted 15 developers Emergency Use Authorization (EUA) for COVID-19 serology tests, which detect antibodies against SARS-CoV-2 in a patient’s blood, a sign that he or she has encountered the virus and mounted some degree of immune response. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article